Malayan Banking Bhd (Maybank) reported a 7.9% jump in its bottomline in its 2024 financial year (FY24), driven by strong ...

PEG's fourth-quarter revenues beat the Zacks Consensus Estimate by 6.6%. However, the top line decreases 5.4% from the ...

Vitiligo is a condition characterized by a loss of pigment (melanin), which results in the most common symptom: white or ...

TEM's fourth-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.

KTOS' Q4 results are likely to benefit from solid segmental revenue performance amid the adverse impacts of higher ...

Children with vitiligo do not have a higher risk for visual acuity deficits than healthy peers, a study suggests.

The project is progressing as per the timetable for completion by second half of 2025, with a capacity of 350,000 tonnes per ...

Mesaieed Petrochemical Holding Company (MPHC) held its Annual General Assembly meeting, yesterday. Chairman of the Board of ...

Bioimpedance Devices MarketThe global bioimpedance devices market is projected to grow from USD 650.5 million in 2024 to USD ...

Despite some companies posting record results, investors are marking down share prices on valuation and other concerns.

Citi raised the firm’s price target on Travere Therapeutics (TVTX) to $35 from $31 and keeps a Buy rating on the shares. The firm anticipates ...